Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Mologen initiates lung cancer trial of MGN-1703 in Belgium

March 27, 2014

Siltuximab receives positive CHMP opinion supporting approval in multicentric Castleman's disease

March 25, 2014

ArevaMed presents phase I data for 212Pb-TCMC-trastuzumab

March 24, 2014

Phase III trial of GSK's MAGE-A3 immunotherapeutic in NSCLC misses first co-primary endpoints

March 21, 2014

Advaxis and UCSF to assess cancer immunotherapy constructs

March 19, 2014

Igenica Biotherapeutics doses first patient in phase I study of IGN-523

March 19, 2014

Japanese approval for Poteligeo in PTCL and CTCL

March 17, 2014

U.S. researchers prepare new MAbs for diagnostic and treatment of cancer

March 17, 2014

Peregrine Pharmaceuticals' PS-targeted programs supported by recent preclinical data

March 14, 2014

Fate Therapeutics begins phase II trial of ProHema for hematologic malignancies

March 13, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....